Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof.

Abstract: The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.

Abstract: The present invention relates to a kit for determining susceptibility to an allergic reaction for a subject. The kit includes a probe for identifying a target biomarker, and an instruction that indicates the subject's susceptibility to the allergic reaction. The present invention also relates to a method of predicting susceptibility to an allergic reaction for a subject and treating and/or preventing the allergic reaction.

Abstract: The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.

Abstract: The present invention generally relates to compositions and methods for inducing an adaptive immune response in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof.

Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof.

Abstract: The present invention relates to mast cell cultures that are derived from hematopoietic progenitors and the use thereof. The invention describes a method for generating in-vitro cultures of human mast cells with functional phenotype of connective tissue-type mast cells. By monitoring the levels of chemokines released into the medium, such mast cell cultures can be used as a cell-based assay to assess regulation of mast cell functions and pharmacological activities of tryptase inhibitors.

Abstract: The present invention relates to mast cell cultures that are derived from hematopoietic progenitors and the use thereof. The invention describes a method for generating in-vitro cultures of human mast cells with functional phenotype of connective tissue-type mast cells. By monitoring the levels of chemokines released into the medium, such mast cell cultures can be used as a cell-based assay to assess regulation of mast cell functions and pharmacological activities of tryptase inhibitors.

Abstract: The present invention relates to mast cell cultures that are derived from hematopoietic progenitors and the use thereof. The invention describes a method for generating in-vitro cultures of human mast cells with functional phenotype of connective tissue-type mast cells. By monitoring the levels of chemokines released into the medium, such mast cell cultures can be used as a cell-based assay to assess regulation of mast cell functions and pharmacological activities of tryptase inhibitors.

Abstract: Non-human transgenic animal models and cells derived therefrom are provided for RabGEF1 function. RabGEF1 is a negative regulator of Fc?RI-dependent mast cell activation and T cell activation via the T cell receptor and a lack of RabGEF1 results in the development of skin inflammation in vivo. The mast cells derived from such animals exhibit enhanced Ras-mediated signaling and functional responses when activated through high affinity IgE receptors. These cells show significant potentiation of IgE and antigen-dependent secretion of 3 classes of mast cell mediators, providing a useful source of mast cells for screening assays.

Abstract: Non-human transgenic animal models and cells derived therefrom are provided for RabGEF1 function. RabGEF1 is a negative regulator of Fc?RI-dependent mast cell activation and T cell activation via the T cell receptor and a lack of RabGEF1 results in the development of skin inflammation in vivo. The mast cells derived from such animals exhibit enhanced Ras-mediated signaling and functional responses when activated through high affinity IgE receptors. These cells show significant potentiation of IgE and antigen-dependent secretion of 3 classes of mast cell mediators, providing a useful source of mast cells for screening assays.

Abstract: Cationic liposomes with immunostimulatory nucleic acids are shown to stimulate the innate immune response, and synergistic combinations of such liposomal nucleic acids and therapeutic antibodies are provided to dramatically improve antibody dependent cellular cytotoxicity and target cell lysis.

Abstract: Novel gene, rin2, and encoded protein are disclosed which can inhibit the functional response induced by Ras-dependent signaling pathways are disclosed. Methods of inhibiting or enhancing Ras-dependent signaling and methods of treatment utilizing Rin2 are also disclosed.

Abstract: A method for reducing the severity of chemotherapy side effects in cancer patients by administering thymosin &agr;1 in conjunction with the administration of a chemotherapy agent to the patient. As a result of the reduction of post-chemotherapy side effects, patients experience an increase in the quality of life.

Abstract: Novel gene, rin2, and encoded protein are disclosed which can inhibit the functional response induced by Ras-dependent signaling pathways are disclosed. Methods of inhibiting or enhancing Ras-dependent signaling and methods of treatment utilizing Rin2 are also disclosed.